What Is Buprenorphine? And Why Is the Comparison to Kratom Important?
The Comparison at a Glance
| Property | Buprenorphine | Mitragynine |
|---|---|---|
| Receptor type | μ-Opioid receptor | μ-Opioid receptor |
| Agonism type | Partial agonist | Partial agonist |
| Clinical authorisation | Yes (OST, pain) | No |
| Standardisation | Pharmaceutical purity | Variable by batch |
Why the Comparison Matters
The pharmacological similarity explains why the "kratom for opioid withdrawal" approach is not pharmacologically absurd – it has a mechanistic basis. It shows which research questions need asking. It illustrates the research gap: buprenorphine has decades of clinical studies, mitragynine has almost none. In countries without adequate substitution medication access, people use kratom from necessity, not ignorance.
Conclusion
Both are partial μ-opioid receptor agonists. That is where equivalence ends. The comparison shows why kratom research matters – not that kratom can or should replace buprenorphine.
Legal Notice: This article is for informational purposes only and does not constitute legal advice. The content is not intended to encourage consumption. Laws may change; the applicable regulations and information from official authorities shall prevail. Image source: https://www.kratoein.com/